ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
18/09/2022
Voltar para busca
Dado oficial do USPTO
O ONKO-INNATE
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
32
Atualização mais recente
18/09/2022
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
5, 42
Data de depósito
23/07/2020
Data de registro
18/01/2022
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
18/01/2022
Última transação
18/01/2022
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
3
Tipo de titular
99
Localização do titular
AU
Examinador
LINDEMYER, ANKHI
Unidade examinadora
N50
Localização atual
PUBLICATION AND ISSUE SECTION
Descrição da marca
The mark consists of the letter "O" comprised of circles and drops floating away and the wording "ONKO-INNATE".
Titulares e representantes
Titulares
oNKo-innate Pty Ltd
Representantes
Andrew S. Ehard Merchant & Gould P.C.
Classificação técnica
Classes Nice
Classe 5Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical drugs for the treatment of cancer and immune cell related disorders; pharmaceutical preparations for the treatment of cancer and immune cell related disorders; stem cells for medical purposes; living cells for medical use; pharmaceutical and biological preparations for the treatment of cancer; biological preparations for medical use for the treatment of cancer and immune cell related disorders; chemicals for pharmaceutical use for the treatment of cancer and immune cell related disorders
Classe 42
Scientific research; pharmaceutical researchdevelopment and testing services; scientific researchpreparation of scientific reports; advisory services relating to immunological product development and testing; scientific researchdesignanalysis and testing of pharmaceutical products; conducting scientific and medical research and clinical trials; scientific research in the field of immunology and cancer treatment; scientific research and testing in the field of natural killer cells; provision of scientific information in the field of immunologycancer treatment and the treatment of immune cell related disorders; scientific and technical analysisscientific researchanalysis and testing in the field of immunologycancer treatment and the treatment of immune cell related disorders; scientific research consultancy in the field of immunologycancer treatment and the treatment of immune cell related disorders; scientific research in the field of pharmacy; medical research; research and development of products; research relating to pharmaceuticals
Publicações
Histórico de despachos e eventos da marca no USPTO.
32 publicações encontradas
NREP
NEW REPRESENTATIVE AT IB RECEIVED
14/08/2022
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
18/07/2022
FICS
FINAL DISPOSITION NOTICE SENT TO IB
28/06/2022
FIMP
FINAL DISPOSITION PROCESSED
27/06/2022
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
18/04/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
18/01/2022
ETOP
EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
12/12/2021
DOCK
ASSIGNED TO EXAMINER
03/11/2021
ETOF
EXTENSION OF TIME TO OPPOSE RECEIVED
01/09/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/08/2021
PUBO
PUBLISHED FOR OPPOSITION
03/08/2021
GPNX
NOTIFICATION PROCESSED BY IB
01/08/2021
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
14/07/2021
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
14/07/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
14/07/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
30/06/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
21/05/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
20/05/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
20/05/2021
ATRV
ATTORNEY REVIEW COMPLETED
06/04/2021
LIME
LIMITATION FROM THE IB - REQUEST EXAM REVIEW
01/03/2021
LIMG
LIMITATION OF GOODS RECEIVED FROM IB
13/02/2021
RFNT
REFUSAL PROCESSED BY IB
20/12/2020
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
03/12/2020
RFRR
REFUSAL PROCESSED BY MPU
03/12/2020
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
14/11/2020
CNRT
NON-FINAL ACTION WRITTEN
13/11/2020
DOCK
ASSIGNED TO EXAMINER
09/11/2020
MAFR
APPLICATION FILING RECEIPT MAILED
01/09/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
28/08/2020
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
27/08/2020
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace O ONKO-INNATE ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.